We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
Read MoreHide Full Article
Expanding its tissue technology portfolio, Integra LifeSciences Holdings Corporation (IART - Free Report) recently announced the launch of collagen matrices — Revize/Revize-X — for plastic and reconstructive surgery.
Available in solid and 2:1 meshed configuration, Revize/Revize-X Collagen Matrix are derived from fetal bovine dermis which contains high levels of Type III collagen. Per the company, Revize/Revize-X will aid in implanting and strengthening weak soft tissue along with surgical repairing of damaged or ruptured soft tissue membranes.
Solidifying its footprint in plastic and reconstructive surgery, this global medical technology company recently announced the launch of a collagen matrix SurgiMend PRS Meshed — featuring a 2: 1 meshing pattern. In a parallel release, Integra announced the launch of SurgiMend PRS Meshed for pre- and sub-pectoral breast reconstruction in Europe.
In May, the company launched SurgiMend MP — a collagen matrix for complex abdominal hernia repair — featuring a highly macroporous design that enables fluid drainage. In the same month, the company announced the European launch of Dermal Regeneration Template Single Layer "Thin" for dermal repair defects reconstruction through a "one-step" procedure.
Interestingly, the company’s Orthopedics and Tissue Technologies segment accounted for 43.3% of the company’s total revenues in the last reported quarter. The latest launch is expected to boost the segment’scontribution.
Integra’s efforts to grow in the plastic and reconstructive surgery market seem to be strategic as per Technavio data published in Business Wire. Per the report, the global plastic surgery products market is expected to reach a value of around $15 billion, at a CAGR of 9% between 2016 and 2020.
We believe growing consciousness about appearance among individuals, increasing awareness and rising expenditure in healthcare and technological advancements are likely to drive demand for cosmetic surgeries. Thus, the latest launch will help Integra cash in on the opportunities in this niche market.
Share Price Performance
In the last six months, Integra has been consistently trading above the broader industry. To date, the stock has rallied 25.3%, higher than the 12.5% gain of the broader industry.
Zacks Rank & Key Picks
Integra currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 39% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 35.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 21.4% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
Expanding its tissue technology portfolio, Integra LifeSciences Holdings Corporation (IART - Free Report) recently announced the launch of collagen matrices — Revize/Revize-X — for plastic and reconstructive surgery.
Available in solid and 2:1 meshed configuration, Revize/Revize-X Collagen Matrix are derived from fetal bovine dermis which contains high levels of Type III collagen. Per the company, Revize/Revize-X will aid in implanting and strengthening weak soft tissue along with surgical repairing of damaged or ruptured soft tissue membranes.
Solidifying its footprint in plastic and reconstructive surgery, this global medical technology company recently announced the launch of a collagen matrix SurgiMend PRS Meshed — featuring a 2: 1 meshing pattern. In a parallel release, Integra announced the launch of SurgiMend PRS Meshed for pre- and sub-pectoral breast reconstruction in Europe.
In May, the company launched SurgiMend MP — a collagen matrix for complex abdominal hernia repair — featuring a highly macroporous design that enables fluid drainage. In the same month, the company announced the European launch of Dermal Regeneration Template Single Layer "Thin" for dermal repair defects reconstruction through a "one-step" procedure.
Interestingly, the company’s Orthopedics and Tissue Technologies segment accounted for 43.3% of the company’s total revenues in the last reported quarter. The latest launch is expected to boost the segment’scontribution.
Integra’s efforts to grow in the plastic and reconstructive surgery market seem to be strategic as per Technavio data published in Business Wire. Per the report, the global plastic surgery products market is expected to reach a value of around $15 billion, at a CAGR of 9% between 2016 and 2020.
We believe growing consciousness about appearance among individuals, increasing awareness and rising expenditure in healthcare and technological advancements are likely to drive demand for cosmetic surgeries. Thus, the latest launch will help Integra cash in on the opportunities in this niche market.
Share Price Performance
In the last six months, Integra has been consistently trading above the broader industry. To date, the stock has rallied 25.3%, higher than the 12.5% gain of the broader industry.
Zacks Rank & Key Picks
Integra currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 39% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 35.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 21.4% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>